Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized Crossover Study to Assess the Subjective Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users

NCT04110535 is registered in ClinicalTrials.gov with Paion UK Ltd. as lead sponsor.

NCT NCT04110535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04110535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized Crossover Study to Assess the Subjective Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users
Lead sponsor
Paion UK Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 23, 2015
Completion date
October 6, 2015
Enrollment
83 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

abuse, drug